Galapagos reports early clinical results for SIK inhibitor
Novel drug candidate found to be generally safe and well-tolerated in inflammatory indications
Read More
Tag: SIK inhibitor
- European life sciences coalition launched to boost investment ecosystem
- 99mtc‑maraciclatide granted fast track status for ILD imaging
- Bioxytran reports rapid viral clearance in phase 2 trial
- Thx Pharma and Biocodex sign rare disease licensing deal
- AstraZeneca bladder cancer therapy wins NICE backing
